Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution1 total trials

N/ANon-phased studies

1(100.0%)

Highest Phase Reached

Unknown

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

N/A

Trials by Phase

N/A1 (100.0%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completednot_applicable

Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes

NCT01042301

completed

Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia

NCT02520895

completed

Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients

NCT01121068

Clinical Trials (3)

Showing 3 of 3 trials

NCT01042301Not Applicable

Profiling of Original Cellular and Humoral Biomarkers of Type 1 Diabetes

Completed

NCT02520895

Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia

Completed

NCT01121068

Monthly Follow up of Interferon Gamma Releasing Assay (IGRA) Among Health-care Workers Treating Tuberculosis (TB) Patients

Completed

All 3 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 3